Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8162436 | 0.78 | TP53 (0.62) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL5376137 | 0.77 | SMN1; SMN2 (0.39) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL3831656 | 0.76 | ALDH1A1 (0.50) | MAPTKDM4EALDH1A1TP53ALOX12 | |
| SCHEMBL26115350 | 0.76 | KDM4E (0.45) | MAPTMAPK1KDM4EALDH1A1GAA | |
| SCHEMBL16822007 | 0.74 | KCNN4 (0.58) | MAPTKCNN4KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL3834925 | 0.73 | KMT2A (0.47) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL21486440 | 0.72 | MAPT (0.45) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL30332521 | 0.72 | MAPT (0.45) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL6765900 | 0.72 | KDM4E (0.53) | MAPTMAPK1KDM4EALDH1A1TP53 | |
| SCHEMBL8163621 | 0.71 | LMNA (0.49) | MAPTMAPK1ALDH1A1TP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548525-B2 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
| US-6271237-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-1999032454-A9 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARM CO (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1042299-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032454-A1 | NITROGEN CONTAINING HETEROAROMATICS WITH ORTHO-SUBSTITUTED P1'S AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016326-A1 | Nitrogen containing heteroaromatics with ortho-substituted P1's as factor Xa inhibitors | F12, F11, F2 | MAPT 4556/4885KCNN4 913/4885MAPK1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.